{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:44:43Z","timestamp":1764585883188,"version":"3.46.0"},"reference-count":38,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>To meet the need for effective treatments during the COVID\u201019 Public Health Emergency, the U.S. government sought to accelerate the discovery and development of new antiviral treatments\u2014a process that normally took 4\u201312\u2009years. The government changed many features of the established system, selecting the investigational drugs, sponsoring or conducting the clinical testing, and purchasing and managing the distribution of the successful products.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We focused on novel therapeutic agents for COVID\u201019 that were funded, clinically tested, and\/or received Emergency Use Authorization during the Public Health Emergency from January 2020 to May 2023. The primary sources were the public records of the National Institutes of Health, the U.S. Food and Drug Administration, and the Biomedical Advanced Research and Development Authority. Excluded were vaccines, devices, diagnostic tests, and new indications for approved drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In less than 24\u2009months, the emergency program developed, tested, approved, and distributed eight new therapeutic products, including six monoclonal antibodies and two new oral antivirals. In addition, 11 other investigational agents were funded or tested under the emergency program but did not receive Emergency Use Authorization. More than 30 million courses of treatment were distributed at a cost of $29 billion or $881 per patient. By the end of the emergency, viral mutations and rapidly growing population immunity rendered the new products ineffective in almost all patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The emergency program was dramatically effective in finding and testing new drug treatments using a variety of clinically relevant endpoints and serving varied patient populations. Planning for future pandemics should include a global network of clinical testing centers that were key to a rapid response. Research is needed to discover more durable antiviral treatments, especially in settings where mutation and population immunity are subject to rapid change.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/phar.70070","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:11:14Z","timestamp":1761135074000},"page":"780-790","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Developing New Drugs for the\n                    <scp>COVID<\/scp>\n                    \u201019 Emergency: Anatomy of the U.S.\u00a0Response"],"prefix":"10.1002","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0994-836X","authenticated-orcid":false,"given":"Thomas J.","family":"Moore","sequence":"first","affiliation":[{"name":"Bloomberg School of Public Health Johns Hopkins University  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9459-4898","authenticated-orcid":false,"given":"Mariana P.","family":"Socal","sequence":"additional","affiliation":[{"name":"Bloomberg School of Public Health Johns Hopkins University  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1845-1523","authenticated-orcid":false,"given":"Gerard","family":"Anderson","sequence":"additional","affiliation":[{"name":"Bloomberg School of Public Health Johns Hopkins University  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"volume-title":"Prescription for Disaster: The Hidden Dangers in Your Medicine Cabinet","year":"1998","author":"Moore T. J.","key":"e_1_2_9_2_1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1166"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100983"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573\u2010023\u201000672\u2010y"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41564\u2010023\u201001356\u20104"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae497"},{"key":"e_1_2_9_8_1","unstructured":"Administration for Strategic Preparedness & Response \u201cDetermination That a Public Health Emergency Exists \u201d2020 accessed September 23 2025 https:\/\/aspr.hhs.gov:443\/legal\/PHE\/Pages\/2019\u2010nCoV.aspx."},{"key":"e_1_2_9_9_1","unstructured":"Office of the Commissioner Food and Drug Administration \u201cEmergency Use Authorization \u201d2025 accessed September 25 2025 https:\/\/www.fda.gov\/emergency\u2010preparedness\u2010and\u2010response\/mcm\u2010legal\u2010regulatory\u2010and\u2010policy\u2010framework\/emergency\u2010use\u2010authorization."},{"key":"e_1_2_9_10_1","unstructured":"\u201cAdministration for Strategic Preparedness & Response. Department of Health and Human Services \u201daccessed September 20 2025 https:\/\/aspr.hhs.gov\/Pages\/Home.aspx."},{"key":"e_1_2_9_11_1","unstructured":"Biomedical Advanced Research and Development Authority \u201cMedical Countermeasures | COVID\u201019 Portfolio \u201daccessed September 23 2025 https:\/\/www.medicalcountermeasures.gov\/barda\/barda\u2010covid\u201019\u2010response\/covid\u201019\u2010portfolio."},{"key":"e_1_2_9_12_1","unstructured":"\u201cJPEO\u2010CBRND: Joint Program Executive Office for Chemical Biological Radiological and Nuclear Defense \u201daccessed September 23 2025 https:\/\/www.jpeocbrnd.osd.mil\/."},{"key":"e_1_2_9_13_1","unstructured":"U.S. Department of Health and Human Services \u201cOffice of the Secretary FOIA Library\/Electronic Reading Room \u201d2024 accessed September 23 2025 https:\/\/www.hhs.gov\/foia\/electronic\u2010reading\u2010room\/index.html."},{"key":"e_1_2_9_14_1","unstructured":"Center for Drug Evaluation and Research Food and Drug Administration \u201cEmergency Use Authorizations for Drugs and Non\u2010Vaccine Biological Products \u201d2025 accessed September 23 2025 https:\/\/www.fda.gov\/drugs\/emergency\u2010preparedness\u2010drugs\/emergency\u2010use\u2010authorizations\u2010drugs\u2010and\u2010non\u2010vaccine\u2010biological\u2010products."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/M21\u20101269"},{"key":"e_1_2_9_16_1","unstructured":"\u201cACTIV\u20102: A Study for Outpatients With COVID\u201019 \u201daccessed July 22 2025 https:\/\/clinicaltrials.gov\/study\/NCT04518410."},{"key":"e_1_2_9_17_1","unstructured":"ClinicalTrials.gov \u201cACTIV\u20103: Therapeutics for Inpatients With COVID\u201019 (TICO). National Institute of Allergy and Infectious Diseases \u201d2023 accessed December 28 2024 https:\/\/clinicaltrials.gov\/study\/NCT04501978."},{"key":"e_1_2_9_18_1","unstructured":"Merck \u201cMerck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGREVIO (Molnupiravir) \u201d2023 accessed March 20 2025 https:\/\/www.merck.com\/news\/merck\u2010and\u2010ridgeback\u2010provide\u2010update\u2010on\u2010eu\u2010marketing\u2010authorization\u2010application\u2010for\u2010lagevrio\u2010molnupiravir\u20102\/."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2021.1960819"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(22)00311\u20105"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.04.012"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.35077"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044"},{"key":"e_1_2_9_24_1","unstructured":"Merck \u201cA Phase 2\u20133 Randomized Placebo\u2010Controlled Double\u2010Blind Clinical Study to Evaluate the Efficacy Safety and Pharmacokinetics of MK\u20104482 in Non\u2010Hospitalized Adults With COVID\u201019 \u201d2023 accessed September 22 2025 https:\/\/clinicaltrials.gov\/study\/NCT04575597."},{"key":"e_1_2_9_25_1","unstructured":"Merck \u201cMerck Announces Supply Agreement With U.S. Government for Molnupiravir an Investigational Oral Antiviral Candidate for Treatment of Mild to MOderate COVID\u201019 \u201d2021 https:\/\/www.merck.com\/news\/merck\u2010announces\u2010supply\u2010agreement\u2010with\u2010u\u2010s\u2010government\u2010for\u2010molnupiravir\u2010an\u2010investigational\u2010oral\u2010antiviral\u2010candidate\u2010for\u2010treatment\u2010of\u2010mild\u2010to\u2010moderate\u2010covid\u201019\/."},{"key":"e_1_2_9_26_1","unstructured":"Merck \u201cMerck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients With Mild or Moderate COVID\u201019 in Positive Interim Analysis of Phase 3 Study \u201d2021 accessed April 26 2025 https:\/\/www.merck.com\/news\/merck\u2010and\u2010ridgebacks\u2010investigational\u2010oral\u2010antiviral\u2010molnupiravir\u2010reduced\u2010the\u2010risk\u2010of\u2010hospitalization\u2010or\u2010death\u2010by\u2010approximately\u201050\u2010percent\u2010compared\u2010to\u2010placebo\u2010for\u2010patients\u2010with\u2010mild\u2010or\u2010moderat\/."},{"key":"e_1_2_9_27_1","unstructured":"Center for Drug Research and Evaluation Food and Drug Administration \u201cEmergency Use Authorization for Molnupiravir 200 Mg Capsules \u201d2021 https:\/\/www.fda.gov\/media\/155241\/download?attachment."},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100044"},{"key":"e_1_2_9_29_1","unstructured":"Food and Drug Administration \u201cFinal Summary Minutes of the Antimicrobial Drugs Advisory Committee Meeting \u201d2021 https:\/\/web.archive.org\/web\/20241108181048\/https:\/\/www.fda.gov\/media\/154970\/download."},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(22)02597\u20101"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542"},{"key":"e_1_2_9_32_1","unstructured":"Pfizer \u201cPfizer's Novel COVID\u201019 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2\/3 EPIC\u2010HR Study \u201d2021 accessed July 23 2024 https:\/\/www.pfizer.com\/news\/press\u2010release\/press\u2010release\u2010detail\/pfizers\u2010novel\u2010covid\u201019\u2010oral\u2010antiviral\u2010treatment\u2010candidate."},{"key":"e_1_2_9_33_1","unstructured":"\u201cPfizer to Provide U.S. Government With 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID\u201019 | Pfizer \u201daccessed September 29 2025 https:\/\/www.pfizer.com\/news\/press\u2010release\/press\u2010release\u2010detail\/pfizer\u2010provide\u2010us\u2010government\u201010\u2010million\u2010treatment\u2010courses."},{"key":"e_1_2_9_34_1","unstructured":"Pfizer \u201cAn Interventional Efficacy and Safety Phase 2\/3 Double\u2010Blind 2\u2010Arm Study to Investigate Orally Adinistered PF\u201007321322\/Ritonavair \u201d2022 https:\/\/clinicaltrials.gov\/study\/NCT05011513."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309003"},{"key":"e_1_2_9_36_1","unstructured":"\u201cPfizer Announces Additional Phase 2\/3 Study Results Confirming Robust Efficacy of Novel COVID\u201019 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death | Pfizer \u201daccessed July 13 2024 https:\/\/www.pfizer.com\/news\/press\u2010release\/press\u2010release\u2010detail\/pfizer\u2010announces\u2010additional\u2010phase\u201023\u2010study\u2010results."},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100694"},{"key":"e_1_2_9_38_1","unstructured":"Canadian Institute of Health Research \u201cCanTreatCOVID: Canadian Adaptive Platform Trial of Treatments for COVID in Community Setting \u201dhttps:\/\/cantreatcovid.org\/news\u2010updates."},{"key":"e_1_2_9_39_1","unstructured":"University of Oxford \u201cPanoramic Platform Trial of Novel Antivirals for Early Treatment of COVID\u201019 in the Community \u201daccessed September 22 2025 https:\/\/www.panoramictrial.org\/results."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.70070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:41:20Z","timestamp":1764585680000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.70070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/phar.70070"],"URL":"https:\/\/doi.org\/10.1002\/phar.70070","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"2025-08-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}